The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 27, 2015

Filed:

Jun. 06, 2008
Applicants:

Marc Chevrier, Collegeville, PA (US);

William W. Freimuth, Gaithersburg, MD (US);

Zhenshao Zhong, Potomac, MD (US);

Daniel Odenheimer, Potomac, MD (US);

Inventors:

Marc Chevrier, Collegeville, PA (US);

William W. Freimuth, Gaithersburg, MD (US);

Zhenshao Zhong, Potomac, MD (US);

Daniel Odenheimer, Potomac, MD (US);

Assignee:

Human Genome Sciences, Inc., Rockville, MD (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61P 25/00 (2006.01); A61K 38/19 (2006.01); C07K 14/705 (2006.01); C07K 16/28 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
A61K 38/19 (2013.01); C07K 14/70575 (2013.01); C07K 16/2875 (2013.01); C07K 16/2887 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2316/96 (2013.01); C07K 2317/56 (2013.01);
Abstract

The present invention relates to methods and compositions for use in treatment of patients with autoantibody positive disease. In a specific embodiment, the present invention relates to a method of treating a patient that has an ANA titer of 1:80 or greater and/or greater than or equal to 30 IU/ml of anti-dsDNA antibodies in his/her blood plasma or serum comprising administering a therapeutically effective amount of an immunomodulatory agent, such as an antagonist of Neutrokine-alpha. Additionally provided is a method of reducing the frequency and/or quantity of corticosteroid administration to patients. In preferred embodiments, the patient has systemic lupus erythematosus. Methods for determining if a lupus patient is responding to medical treatment are also provided.


Find Patent Forward Citations

Loading…